Latest information on COVID-19
Support teaching, research, and patient care.
New technologies in the area of catheters, clamps, and, visualization devices for aid in cardiac surgery; distribution of, cardioplegia, both anterograde and retrograde as determined by, techniques in technetium pyro-phosphate scans; glucose insulin, potassium as an adjunct in cardiac surgery.
Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma
This will be a multi-center, proof of concept phase 0 study to assess the suppression of
p-AKT in Vestibular Schwannoma (VS) and meningiomas by AR-42 in adult patients undergoing
tumor resection. AR-42 is a small molecule which crosses the blood brain barrier (BBB) in
rodents, but the investigators are not certain yet if it will penetrate human VS. Meningiomas
are outside the BBB, but seem to be unusually resistant to all current medical treatments.
The primary endpoint of the bioactivity of suppression of p-AKT by AR-42 was selected as drug
activity seems more informative than bioavailability. Our preclinical data and others have
shown dose dependent suppression of p-AKT by AR-42 in both VS and meningiomas.
Stanford is currently not accepting patients for this trial.
For more information, please contact SPECTRUM, .
View full details
Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Severe, Symptomatic Aortic Stenosis in Intermediate Risk Subjects Who Need Aortic Valve Replacement (SURTAVI).
The purpose of the study is to investigate the safety and efficacy of transcatheter aortic
valve implantation (TAVI) in patients with severe, symptomatic Aortic Stenosis (AS) at
intermediate surgical risk by randomizing patients to either Surgical Aortic Valve
Replacement (SAVR) or TAVI with the Medtronic CoreValve® System.
Single Arm: The purpose of this trial is to evaluate the safety and effectiveness of
transcatheter aortic valve implementation (TAVI) in patients with severe symptomatic Aortic
Stenosis (AS) at intermediate surgical risk with TAVI. This is a non-randomized phase of the
pivotal clinical trial.